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ABSTRACT
Cardiac dysfunction is correlated with detrimental prognosis of sepsis and
contributes to a high risk of mortality. After an initial hyperinflammatory reaction,
most patients enter a protracted state of immunosuppression (late sepsis) that
alters both innate and adaptive immunity. The changes of cardiac function in late
sepsis are not yet known. MicroRNA-155 (miR-155) is previously found to play
important roles in both regulations of immune activation and cardiac function. In
this study, C57BL/6 mice were operated to develop into early and late sepsis phases,
and miR-155 mimic was injected through the tail vein 48 h after cecal ligation and
puncture (CLP). The effect of miR-155 on CLP-induced cardiac dysfunction was
explored in late sepsis. We found that increased expression of miR-155 in the
myocardium protected against cardiac dysfunction in late sepsis evidenced by
attenuating sepsis-reduced cardiac output and enhancing left ventricular systolic
function. We also observed that miR-155 markedly reduced the infiltration of
macrophages and neutrophils into the myocardium and attenuated the inflammatory
response via suppression of JNK signaling pathway. Moreover, overexpression of
β-arrestin 2 (Arrb2) exacerbated the mice mortality and immunosuppression in
late sepsis. Furthermore, transfection of miR-155 mimic reduced Arrb2 expression,
and then restored immunocompetence and improved survival in late septic mice.
We conclude that increased miR-155 expression through systemic administration
of miR-155 mimic attenuates cardiac dysfunction and improves late sepsis
survival by targeting JNK associated inflammatory signaling and Arrb2 mediated
immunosuppression.

INTRODUCTION

a hyperinflammatory status with excessive production
of pro-inflammatory mediators by macrophages
and neutrophils [3, 4]. Until recently, most research
was focused on ameliorating the hyperinflammatory
response of the disorder, however, clinical trials
using anti-inflammatory treatment failed to reduce
overall sepsis mortality [5]. In a postmortem study of
sepsis, more than 70% of patients died after an early/
acute hyperinflammatory phase and most patients
enter a state of late/chronic hypoinflammation and

Sepsis is defined as a systemic inflammatory
response to life-threatening infection with the presence
of organ failure [1]. Despite progress in antibiotic
treatment and prompt institution of life support,
sepsis remains the major cause of death in intensive
care units [2]. The mechanism involved in the host
immune response to sepsis is debated. Traditionally,
the immune response was considered to be typified by
www.impactjournals.com/oncotarget
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immunosuppression [6, 7]. So far there is no effective
therapy for late sepsis.
Growing evidence suggests that cardiovascular
dysfunction as a major complication of sepsis
is correlated with worse performance and poor
prognosis, and cardiac dysfunction increases the risk
of mortality rates up to 70% in sepsis/septic shock
[8, 9]. Therefore, it is a critically unmet need to
clarify the mechanisms of cardiac dysfunction caused
by sepsis and explore effective treatment to ameliorate
the sepsis prognosis.
Over the past few years, microRNAs (miRs)
have proved to be critical regulators of physiological
homeostasis in the cardiovascular system [10, 11]. A
subset of miRs has been identified as potential prognostic
indicators of heart failure following acute myocardial
infarction (MI). Using a high-throughput array method,
serum expression of miR-155 and miR-380 in patients
who experienced cardiac death were approximately
3-4 fold higher compared with those who returned for
their 1-year follow-up [12]. It has been shown that miR155 exerts an antiangiogenic but proarteriogenic role
in the regulation of neovascularization, and miR-155
down- regulation would result in impaired arteriogenesis
after MI and could exacerbate further injury to the
myocardium [13]. However, the role of miR-155 in the
progression of cardiac dysfunction in sepsis has not yet
been elucidated.
β-arrestin 2 (Arrb2), a multifunctional regulator
of G protein-coupled receptors with especially high
expression in cardiovascular tissues, can modulate
a diverse array of biological processes [14, 15].
Increasing evidence suggests that Arrb2 plays a crucial
role in regulating systemic immune responses and the
kinetics of Arrb2-mediated signaling is tissue-dependent
[15, 16]. Our previous studies found that miR-155
could directly target the 3′-UTR of Arrb2 mRNA in a
sequence-specific manner and there is a loop pathway
between Arrb2 and miR-155 to promote the transition of
cardiac stem cells into cardiomyocytes [17]. However,
the effect of Arrb2 on cardiac function during late sepsis
remains unknown.
In the present study, we demonstrated that
increased expression of miR-155 protects against
cardiac dysfunction in late sepsis. We also observed
that miR-155 markedly reduces the infiltration of
macrophages and neutrophils into the myocardium and
attenuates the inflammatory response via suppression
of JNK activity. Overexpression of Arrb2 exacerbates
the mortality and immunosuppression in late sepsis
mice. Transfection of miR-155 mimic reduces Arrb2
expression in the myocardium, and restores mice
immunocompetence and improves survival. These
findings suggest that modulation of the miR-155/Arrb2
pathway is capable of preventing late sepsis-induced
cardiac dysfunction.
www.impactjournals.com/oncotarget

In vivo transfection of miR-155 mimic improves
late sepsis survival
Previous study shows that miR-155 was increased in
early sepsis and returned to baseline level in late sepsis [18].
To determine whether increased expression of miR-155
in late phase could impact the sepsis outcome, miR-155
mimic was injected through the tail vein 48 h after CLP to
allow the initiation of sepsis and mortality was monitored
for 28 days. As shown in Figure 1A, circulating miR155 maintain baseline level on day 12 after CLP sepsis,
and miR-155 mimic transfection significantly increased
circulating miR-155 expression. The Kaplan-Meier
survival curve (Figure 1B) indicated that 50% of the miRCon treated septic mice died within 10 days, and 100%
mortality occurred at 24 days after CLP. However, survival
in miR-155 mimic treated septic mice was improved by
67% compared with miR-Con group. Our CLP model is
operated to develop into early and late sepsis phases, which
produces 20-30% mortality during early sepsis (days 1
to 5). We didn’t observe the effect of miR-155 mimic on
mortality until day 6 after CLP. These results suggest that
increased miR-155 expression during late phase prevents
sepsis mortality. In the following experiments, we intended
to identify the underlying mechanism for the protective
effect of miR-155 in late sepsis.

Increased myocardium expression of miR-155
attenuates cardiac dysfunction in late sepsis
Recently, it has been shown that cardiac dysfunction
plays a pivotal role in sepsis- induced mortality [8, 9].
To determine the role of miR-155 in cardiac function
during late sepsis, we firstly measured its level in the
myocardium of septic mice. As shown in Figure 2A, the
miR-155 level was increased approximately 5-fold in
early sepsis (compared to sham control, set at 1-fold), and
returned to baseline level in late sepsis (day 12). After
transfection with miR-155 mimic, the expression of miR155 was increased 24.5-fold compared with sham control
on day 3, and sustained increase around 20-fold on day
12. To evaluate the effect of miR-155 on cardiac function
in late sepsis, we collected hemodynamic parameters
by pressure-volume loop measurement on day 12 after
sepsis. CLP induced significant cardiac dysfunction in
late sepsis mice as evidenced by decreased heart rate
(32.3%) (Figure 2B), EF% (40.6%) (Figure 2C), cardiac
output (61.7%) (Figure 2D), and Pes (39.9%) (Figure 2E)
compared with baseline values. In contrast, miR-155
mimic treatment significantly attenuated CLP-induced
cardiac dysfunction, which increased heart rate by 29.3%,
EF% by 33.5%, cardiac output by 72.8%, and Pes by
47.8% when compared with the untreated CLP group.
Taken together, increased expression of miR-155 in the
47318
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Figure 1: Increased expression of miR-155 in circulation improves late-septic mice survival outcome. Eight- to 10-weeks

C57BL/6 male mice were subjected to CLP, and sham surgical operation served as sham control. miR-155 mimic or miR-Con (80 mg/kg)
was injected through the tail vein 48 h after CLP. (A) After 12 days of CLP, sera were harvested and the expression of miR-155 was
determined by real time PCR. There were four mice per group. *p < 0.05, **p < 0.01, ***p < 0.001 compared with indicated groups. (B)
After 48 h of CLP, mice were transfected with miR-155 mimic or miR-Con and then monitored for survival for up to 28 days. There were
15-18/group. **p < 0.01 compared with miR-Con group.

Figure 2: Increased expression of miR-155 in the myocardium attenuates cardiac dysfunction in late sepsis. Eight- to

10-weeks old C57BL/6 male mice were subjected to CLP or sham surgical operation. miR-155 mimic or miR-Con (80 mg/kg) was injected
through the tail vein 48 h after CLP. (A) After 3 days or 12 days of CLP, hearts were harvested and the level of miR-155 was determined
by real time PCR. There were four mice per group. After 12 days of CLP, cardiac function measurement was analysis by pressure-volume
loop hemodynamic parameters. (B) HR, heart rate. (C) EF, ejection fraction. (D) CO, cardiac output. (E) Pes, left ventricular end-systolic
pressure. There were five mice per group. *p < 0.05, **p < 0.01, ***p < 0.001 compared with indicated groups.
www.impactjournals.com/oncotarget

47319

Oncotarget

myocardium attenuates sepsis-reduced cardiac output and
enhances left ventricular systolic function, which may
improve late sepsis mice survival.

adhesion molecules, such as ICAM-1 and VCAM-1, play
a critical role in inducing inflammatory cells infiltration
into the tissues [19, 20]. Next, we examined the effect
of miR-155 on the expression of adhesion molecules in
the myocardium. As shown in Figure 3D and 3E, there is
more positive staining of ICAM and VCAM-1 in the lateseptic mice myocardium compared with sham control, and
miR-155 mimic transfection attenuated sepsis-mediated
expression of myocardial ICAM-1 and VCAM-1. CLPinduced accumulation of macrophages and neutrophils, or
the expression of ICAM-1 or VCAM-1 in the myocardium
was not affected when treated with miR-Con.

Transfection of miR-155 mimic attenuates
infiltration of macrophages and neutrophils into
the myocardium in late sepsis
It has been reported that the infiltration of
macrophages and neutrophils was markedly increased
early into the myocardium following CLP, which
contributes to cardiac dysfunction during the development
of septic shock [19]. It remains unclear whether this
phenomenon occurs in late sepsis. Figure 3A–3C shows
that macrophages and neutrophils accumulation were
markedly increased in the myocardium during the lateseptic phase. miR-155 mimic transfection significantly
reduced sepsis-induced infiltration of macrophages by
51.2% and neutrophils by 56% into the myocardium when
compared with untreated CLP mice. It is well known that

Transfection of miR-155 mimic suppresses
myocardium pro-inflammatory responses in late
sepsis
Increased infiltration of inflammatory cells into
the myocardium and persistence of an inflammatory
microenvironment contribute to cardiac dysfunction

Figure 3: Transfection of miR-155 mimic prevents infiltration of macrophages and neutrophils into the myocardium
and reduces adhesion molecule expression in late sepsis. miR-155 mimic or miR-Con (80 mg/kg) was transfected through the tail
vein 48 h after CLP. Hearts were harvested 12 days after CLP and sectioned for immunohistochemical staining to identify macrophages (A)
and neutrophils (B). The bar graphs indicate the numbers of infiltrating macrophages and neutrophils in five heart fields (C). Transfection
of miR-155 mimic attenuates late sepsis-induced ICAM-1 (D) and VCAM-1 (E) expression in the myocardium. There were five mice per
group. **p < 0.01, ***p < 0.001 compared with indicated groups.
www.impactjournals.com/oncotarget
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[21]. Then we examined the effect of increased
expression of miR-155 on inflammatory cytokine
production in late-septic mice myocardium. As shown in
Figure 4A, CLP promoted significantly high expression
of pro-inflammatory cytokine TNF-α (3-fold) and IFN-γ
(2.5-fold) compared with sham control (set at 1-fold)
on day 12 after sepsis. miR-155 mimic transfection
reduced TNF-α, IFN-γ production by 48.9%, 45.6%
respectively, and increased anti-inflammatory cytokine
IL-10 (1.8-fold) in the myocardium compared with
untreated CLP mice.
MAPK signaling pathway is an important
component which regulates the expression of inflammatory
cytokines and adhesion molecules [22]. To investigate the
mechanisms responsible for the immunomodulation, we
evaluated the role of miR-155 in activation of MAPKs.
Figure 4B–4D shows that MAPKs were activated in the
late-septic myocardium on day 12 after CLP. Interestingly,
CLP-enhanced JNK phosphorylation in miR-155 mimic
transfected heart was significantly decreased by 49.8%
compared with untreated CLP mice. Whereas the dynamic
of ERK1/2 and p38 activation was not altered after miR155 mimic transfection. Our findings reveal in late sepsis,
JNK is a downstream effector of miR-155. Transfection of

miR-Con did not alter sepsis-induced MAPKs activity in
the myocardium.

Increased miR-155 inhibits cardiac Arrb2
expression in late sepsis
Using luciferase report assay, our previously
research finds miR-155 could target Arrb2 and inhibit
its expression in vitro [17]. In this study, we further
explored the effect of miR-155 on Arrb2 expression in
the late-septic myocardium. As shown in Figure 5A, CLP
increased Arrb2 expression (2-fold) compared to sham
control on day 10 after sepsis. Transfection of miR-155
mimic reduced the level of Arrb2 by 60.5% compared with
untreated CLP mice. Using Arrb2 TG mice (Figure 5B),
we detected the expression of Arrb2 in sham Arrb2 TG
mice was 1.8-fold higher than in sham WT mice. miR155 mimic transfection in Arrb2 TG mice decreased Arrb2
expression by 33.9% compared with sham Arrb2 TG mice.
After CLP in Arrb2 TG mice, transfection of miR-155
mimic suppressed myocardial Arrb2 expression by 55.6%
compared with untreated Arrb2 TG mice in late sepsis.
Transfection of miR-Con did not alter the expression of
Arrb2 in the presence and absence of sepsis.

Figure 4: Transfection of miR-155 mimic attenuates inflammatory responses in late sepsis mice and suppresses p-JNK
expression. miR-155 mimic or miR-Con (80 mg/kg) was transfected through the tail vein 48 h after CLP. (A) Hearts were harvested for

assay of cytokine TNF-α, IFN-γ and IL-10 by qPCR 12 days after CLP. (B–D) Levels of p38, phospho-p38, ERK, phospho-ERK, JNK and
phospho-JNK in the myocardium were examined by immunoblotting with specific antibodies 12 days after CLP. GAPDH expression was
used as an internal control. There were five mice per group. *p < 0.05, **p < 0.01 compared with indicated groups.
www.impactjournals.com/oncotarget
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miR-155 improves Arrb2 TG mice survival and
cardiac dysfunction in late sepsis

cardiac dysfunction through downregulation of the Arrb2
expression level.

To further elucidate the relationship between
miR-155 and Arrb2, and their effect on late-septic mice
survival, we tested miR-155 expression in Arrb2 TG
mice myocardium, meanwhile observed Arrb2 TG mice
survival in late sepsis model. As shown in Figure 6A,
miR-155 expression in CLP Arrb2 TG mice was reduced
by 56.9% compared with in CLP WT mice, meaning that
Arrb2 inhibits the expression of miR-155 and there may be
a loop pathway between Arrb2 and miR-155. Transfection
of miR-155 mimic increased miR-155 expression in the
presence and absence of sepsis, when compared with
untreated Arrb2 TG mice. Figure 6B indicated Arrb2
TG mice were susceptive to late sepsis. Death occurred
with the highest frequency on day 6–10 after sepsis, and
100% mortality occurred at 20 days after CLP. Survival
in miR-155 mimic transfection septic Arrb2 TG mice was
improved by 40% compared with miR-Con group. We
also evaluate the effect of miR-155 on cardiac function
in Arrb2 TG mice at day 10 after sepsis. CLP induced
significant cardiac dysfunction in Arrb2 TG mice by
decreased heart rate (25.1%) (Figure 6C), EF% (48.3%)
(Figure 6D), cardiac output (70.9%) (Figure 6E), and Pes
(46%) (Figure 6F) compared with baseline values. miR155 mimic transfection significantly attenuated sepsisinduced cardiac dysfunction, which increased heart rate
by 25.9%, EF% by 39.1%, cardiac output by 52.4%, and
Pes by 49.6% when compared with the untreated CLP TG
group. Our results indicate that miR-155 may attenuate

Increased miR-155 restores responsiveness of
late-septic Arrb2 TG mice to LPS
Late-septic mice are shown in a state of
immunosuppression, indicated by producing less proinflammatory but more anti-inflammatory cytokines
in our previous study [23]. We hypothesized that mice
which survived late sepsis due to miR-155 mimic
transfection should be immunoreactive, and then they
should resist to a challenge with secondary bacterial
LPS. TG mice that survived (the miR-155 mimic group)
or moribund (the miR-Con group) were pooled at days
6 to 16 after CLP and infected with LPS (10 μg, i.p).
Sham-operated Arrb2 TG mice also received LPS and
served as a positive control. The inflammatory response
was determined by measuring the sera levels of the proinflammatory (TNF-α, INF-γ) and anti-inflammatory
(IL-10, IL-4) cytokines 6 h after LPS challenge. As
shown in Figure 7, the miR-155 mimic transfection
in Arrb2 TG mice significantly increased TNF-α and
INF-γ expression and reduced IL-10 and IL-4 production
compared with miR-Con group. We also observed that
the cytokine profiles in the miR-155 mimic transfection
Arrb2 TG mouse were similar to those in sham-operated
control group, suggesting that increased expression
of miR-155 restored immunoreactivity to LPS, while
Arrb2 TG mice transfection with miR-Con remained
immunosuppressed.

Figure 5: Transfection of miR-155 mimic inhibits myocardium Arrb2 expression in late sepsis. miR-155 mimic or miR-

Con (80 mg/kg) was injected through the tail vein 48 h following CLP. The level of Arrb2 expression in the myocardium was examined by
immunoblotting in WT (A) and Arrb2 TG (B) mice 10 days following CLP. There were five mice per group. *p < 0.05, **p < 0.01 compared
with indicated groups. WT, wild-type; Arrb2 TG, Arrb2 overexpression.
www.impactjournals.com/oncotarget
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precise mechanisms of late sepsis mortality are still
uncertain. Several studies suggest that immune dysfunction,
immune suppression, and persistent catabolism and
inflammation contribute to the deleterious state of chronic
disease [26, 27]. Though some experimental agents, such
as thymosin (NCT00711620) and granulocyte-macrophage
colony stimulating factor (NCT00252915), are being tested

Sepsis is now the leading cause of death in the
intensive care unit. Clinical observation finds that sepsis
has biphasic death distribution, with an initial early peak
at several days and a late peak at several weeks due to
persistent organ injury or failure [24, 25]. However, the

Figure 6: Increased expression of miR-155 attenuates Arrb2 overexpression (TG) mice cardiac dysfunction and
improves survival in late sepsis. Eight- to 10-weeks Arrb2 TG male mice were subjected to CLP or sham surgical operation. miR-

155 mimic or miR-Con (80 mg/kg) was injected through the tail vein 48 h after CLP. (A) Hearts were harvested for assay of miR-155 by
qPCR 10 days after CLP. There were four mice per group. (B) Arrb2 overexpression (TG) mice were transfected with miR-155 mimic or
miR-Con 48 h after CLP and then monitored for survival for up to 28 days. There were 15-18/group. *p < 0.05 compared with Arrb2 TG +
miR-Con group. Ten days after CLP, cardiac function measurement of Arrb2 TG mice was analysis by pressure-volume loop hemodynamic
parameters. (C) HR, heart rate. (D) EF, ejection fraction. (E) CO, cardiac output. (F) Pes, left ventricular end-systolic pressure. There are
five mice per group. *p < 0.05, **p < 0.01, ***p < 0.001 compared with indicated groups.
www.impactjournals.com/oncotarget
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in clinical trials to reconstitute immune responsiveness
in patients with severe sepsis, an effective treatment is
still unavailable until now. Using the late-septic mice
model, our present study demonstrates that transfection
of miR-155 mimic improves sepsis mice survival and
attenuates inflammation-induced myocardium injury. We
also found that Arrb2 exacerbated the mice mortality and
immunosuppression in late sepsis. Increased expression
of miR-155 inhibited cardiac Arrb2 expression, and
then prevented Arrb2 TG mice cardiac dysfunction and
restored late-septic Arrb2 TG mice immunoreactivity to
LPS. Taken together, in vivo miR-155 mimic transfection
attenuates septic sequelae and could pave the way toward
new therapies.
The cardiovascular system plays an important role in
the pathogenesis of sepsis. It has been shown that cardiac
activation of PI3K/Akt-dependent signaling significantly
attenuated myocardial dysfunction and improved

survival in CLP-induced sepsis, which demonstrates a
causal relationship between the protection of myocardial
function and survival in early sepsis [28]. However, as
recent researches suggest that benefits in early sepsis
survival have been forfeited to escalating long-term sepsis
mortality [25, 29], the changes of myocardial function
during late-septic phase are still unclear. Here, we found
CLP also induced significant cardiac dysfunction in
late sepsis mice by decreased heart rate, cardiac output,
EF%, and Pes. Therefore, clarifying the pathogenesis of
late sepsis-induced myocardial dysfunction will provide
benefits to seek specific therapy.
miRNAs are known to modulate normal
physiological and pathophysiological signals within
multiple organ systems [10, 11, 30] . We focused our
attention on the expression of miR-155, which is closely
related to a variety of cardiovascular diseases. miR-155
may be a potential prognostic indicator for heart failure

Figure 7: miR-155 mimic restores Arrb2 overexpression (TG) mice responsiveness to bacterial LPS in late sepsis. At

days 6 to 16 after CLP, mice were moribund (TG+miR-Con group) and a corresponding number of surviving, healthy-appearing mice
(TG+miR-155 group) were challenged with 10 μg of bacterial LPS (i.p.). Sham-operated TG mice and wild-type mice also received LPS
and served as positive controls. After 6 h, sera were obtained and cytokine levels of TNF-α, INF-γ, IL-10 and IL-4 were examined by
ELISA. There are five mice per group. ***p < 0.001 compared with indicated groups.
www.impactjournals.com/oncotarget
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[12]. miR-155 was found to repress eNOS expression,
and regulate endothelium dependent vasorelaxation
[31]. In our study, miR-155 level in the myocardium was
increased during early sepsis and returned to baseline level
in late sepsis. After transfection with miR-155 mimic, the
expression of miR-155 was sustained increase during
late-septic phase. Interestingly, miR-155 mimic treatment
significantly attenuated CLP-induced cardiac dysfunction,
and most importantly, increased miR-155 improved lateseptic mice survival. A wide variety of stimuli, such as
TLR ligands, can increase miR-155 expression, and then
promotes both antimicrobial and antiviral responses
of macrophages [32, 33]. miR-155 is required for the
effective control of streptococcus pneumonia from the
nasopharynx, and antipneumococcal adaptive immunity
is broadly impaired in miR-155 knockout mice [34]. Mice
with a deficiency of miR-155 are highly susceptible to
herpes simplex encephalitis [35], suggesting that miR-155
can enhance the protective immune response to pathogens.
Endothelial cell activation is involved in septic
injury in multiple organs [36]. Systolic cardiac dysfunction
is directly associated with endothelial dysfunction in septic
patients. Myocardium-depressing factors, such as TNF-α,
can increase the expression of ICAM-1 and VCAM-1
in coronary endothelial cells and cardiomyocytes, and
blockade of VCAM-1 or ICAM-1 abrogates LPSinduced cardiac dysfunction [37]. In vivo transfection
of miR-155 mimic, we found miR-155 attenuated late
sepsis-mediated expression of myocardial ICAM-1 and
VCAM-1. Meanwhile, miR-155 significantly reduced
sepsis-induced infiltration of macrophages and neutrophils
into the myocardium. miR-155 is also one of the most
widely studied miRNAs in regulating inflammation. We
observed miR-155 mimic transfection decreased TNF-α,
IFN-γ production and increased anti-inflammatory
cytokine IL-10 in the myocardium, and then attenuates
the inflammatory microenvironment which contributes to
cardiac dysfunction.
MAPK pathways have been implicated in different
aspects of cardiac regulation. The ERK1/2 pathway is
found to be responsive mainly to stimulation of growth
signaling, JNK and p38 are selectively responsive to
pathophysiological stressors, such as infection and
cytokines [15, 38]. Our study shows that levels of
phospho-p38, phospho-ERK and phospho-JNK were all
increased in late-septic myocardium. However, CLPenhanced JNK activity in miR-155 mimic transfected
heart was significantly decreased, whereas the dynamic of
ERK1/2 and p38 activation was not altered. Our findings
indicate JNK is a downstream effector of miR-155 in late
sepsis. Constitutively activated JNK can result in different
aspects of pathological remodeling and may contribute
to systolic dysfunction and slowed conduction velocity
in the heart [39], which is consistent with our detection
results of cardiac function. Previous research shows that
miR-155 downregulates JNK activity through reducing
www.impactjournals.com/oncotarget

the expression of PAK1 in mouse CD4+ T cells [40].
However, the precise mechanisms of miR-155 in the
regulation of JNK activity in late-septic myocardium need
to be further clarified.
Arrb2, a multifunctional adapter protein, plays
important roles in both regulations of immune activation
and cardiac function [14–16]. Arrb2 interacts with the
adaptor TRAF6 to negatively regulate Toll-like receptor
signaling in innate immunity [41]. Arrb2 mediates the
binding of Src homology-containing tyrosine phosphatases
to KIR2DL1 to regulate the inhibitory signaling of NK
cells, and Arrb2-deficient mice were less susceptible to
cytomegalovirus infection compared with wild-type mice
[42]. In our study, Arrb2 TG mice were observed to be
more susceptive to late sepsis than WT mice, as death
occurred with the highest frequency on day 6–10 after
sepsis, which was earlier than in WT mice (day 10–12).
Our previous research has shown that Arrb2 is a direct
target by miR-155 [17], so we further test the hypothesis
that in vivo transfection of miR-155 mimic may reverse
the effect of Arrb2 overexpression. CLP increased Arrb2
expression during the late-septic phase, and miR-155
mimic transfection reduced the level of Arrb2 expression,
and then improved TG mice survival rate. We also
observed the changes of cardiac function in late-septic TG
mice, and found miR-155 mimic transfection significantly
attenuated sepsis-induced cardiac dysfunction. Taken
together, miR-155 may protect cardiac dysfunction
through downregulation of the expression of Arrb2.
Recent studies indicate most patients surviving the
early initial hyperinflammatory phase enter a long-term
immunosuppressive phase [7, 25, 26]. Deaths in this
immunosuppressive phase are mainly due to the deficit
in controlling the primary infection or the susceptibility
of secondary infections [43]. In our present study, lateseptic Arrb2 TG mice were challenged with secondary
bacterial LPS. We found that sepsis Arrb2 TG mice
were immunosuppressive, characterized by reduced
pro-inflammatory (TNF-α, INF-γ) and increased antiinflammatory (IL-10, IL-4) cytokines expression.
Transfection of miR-155 mimic restored TG mice
immunoreactivity to LPS. Interestingly, we also observed
that increased expression of miR-155 in the myocardium
attenuated pro-inflammatory cytokine levels in late sepsis.
Wang and colleagues observed that pharmacological
inhibition of miR-155 using antagomiR improved cardiac
function and suppressed cardiac apoptosis induced
by LPS in acute septic mice [44]. The distinct animal
models with immunological differences (acute sepsis:
hyperinflammatory and late sepsis: immunosuppressive)
could explain these seemingly conflicting experimental
results. These findings highlight the importance of fully
elucidating any miRNA mechanisms in the right time and
in the right cell before pursuing miRNA-based therapies,
and biomarker-guided immunotherapy at the proper
immune phase needs further exploration.
47325
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In summary, the data presented here demonstrated
that miR-155 protects against late sepsis-induced cardiac
dysfunction and improves survival by attenuation of
inflammatory responses at least partially via suppressing
JNK activation. Increased miR-155 also inhibits Arrb2
expression and restores Arrb2 TG mice immunocompetency.
miR-155/Arrb2 may be an effective target in the
management of sepsis and in the field of infectious disease,
and our mice model also provides an important insight into
particular mechanisms of sepsis that may have a comparable
role in humans.

antibiotic (imipenem, 25 mg/kg body weight) or an
equivalent volume of 0.9% saline at 8 and 16 h after CLP.

Transfection and injection of miR-155 mimic

MATERIALS AND METHODS

Both mirVana in vivo ready miR-155 mimic and
negative control (miR-Con) (Ambion, Carlsbad, CA)
were complexed with Invivofectamine 3.0 (Invitrogen)
reagent according to the manufacturer’s protocol and our
previous study [30], and were injected via the tail vein
of male C57BL/6 mice at the dose of 80 mg/kg in 100 µl
volumes. Injection was performed 48 h after CLP to allow
initiation of sepsis.

Experimental animals

Endotoxin challenge

Wild-type (WT) C57BL/6 mice were obtained
from Jackson Laboratory (Bar Harbor, ME). Arrb2
overexpression (TG) mice were reported previously [42].
Briefly, full-length human Arrb2 cDNA from brain cDNA/
λphage library was cloned into pcDNA3 with HA tag
under the control of a human cytomegalovirus promoter.
Then the DNA constructions were injected into fertilized
mice eggs on a C57BL/6 background. Real-time PCR was
used to check the transgene mRNA expression in founder
mice and their offspring. The primers used to identify
transgenic mice were Arrb2, sense 5′-CAG CCA GGA
CCA GAG GAC A-3′, antisense 5′-TGA TAA GCC GCA
CAG AGT T-3′. There is no difference between physical
activity, productivity and life span in WT and Arrb2 TG
mice. 8–10-week old male mice were used in survival
and cardiac function analysis. All mice were maintained
in the Division of Laboratory Animal Resources at East
Tennessee State University (ETSU), a facility accredited
by the Association for the Assessment and Accreditation
of Laboratory Animal Care International. The animal
experimental protocols were approved by the ETSU
Committee on Animal Care.

Surviving septic Arrb2 TG mice that received miR155 mimic or miR-Con between days 6 and 16 after
CLP were challenged (i.p.) with 10 µg of Gram-negative
bacterial LPS (E. coli serotype 0111: B4; Sigma-Aldrich,
St. Louis, MO). Meanwhile, sham-operated Arrb2 TG
mice and wild-type mice also received LPS and served
as a positive control. All mice were sacrificed after 6 h.
Blood was obtained via cardiac puncture and sera were
collected for cytokines measurement.

Cardiac functional analysis
Cardiac function was detected by the SPR-839
instrument (Millar Instruments, Houston, TX, USA), and
heart rate (HR), ejection fraction (EF), left ventricular
end- systolic pressure (Pes), cardiac output (CO) were
calculated as described previously [45]. Briefly, each
mouse was intubated with a 22-gauge soft catheter and
ventilated with a rodent ventilator (Columbus Instruments
International Corp., Columbus, OH, USA), using a tidal
volume of 0.3–0.5 ml and a respiratory rate of 110–120
breaths/min. After left thoracotomy, a microtip pressurevolume catheter was inserted through a 25-gauge apical
stab into the left ventricular to measure the cardiac
function. The signals were continuously recorded using
an ARIA pressure-volume conductance system (Millar
Instruments) connected to a Powerlab/4SPA/D converter
(AD Instruments, Mountain View, CA, USA). All
pressure-volume loop data were analyzed with PVAN3.4
(Millar Instruments). After the functional analysis, the
hearts were removed and perfused for 2 min to remove the
remaining blood. Portions of the midventricle were fixed
for immunological studies.

Cecal ligation and puncture (CLP) late sepsis model
Polymicrobial late sepsis was induced by CLP
as described previously by us [23]. Briefly, mice were
anesthetized via 5.0% isoflurane inhalation in 100% O2 in a
closed chamber and then maintained with 2.5% isoflurane
during surgery. A small anterior abdominal incision was
made, and the cecum was ligated 1 cm proximal to the
terminal of cecum with 2–0 silk, and then was punctured
twice with a 23-gauge needle. A small amount of feces
content was extruded into the abdominal cavity. The
abdomen was then closed in layers with 3-0 silk. Shamoperated mice were processed identically, except without
ligation and puncture. Immediately following surgery,
1 ml 0.9% saline was administrated by intraperitoneal
(i.p.) injection for fluid resuscitation. To create the late
sepsis phenotype, mice were subcutaneously administered
www.impactjournals.com/oncotarget

Quantitative PCR assay of miRs
miRs were isolated from heart tissues using the
mirVanaTM miR isolation kit (Ambion) according to the
manufacturer’s protocol. miR-155 levels were quantified
by quantitative PCR (qPCR) using specific primers
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TaqMan MicroRNA Assay (primer identification numbers:
002571 for mmu-miR-155 and 001973 for snRU6) and
TaqMan Universal PCR Master Mix (Applied Biosystems)
on a Bio-Rad PCR instrument. miR-155 level was
calculated using the 2-ΔΔCT cycle threshold method after
normalization to the snRU6 as an internal control [30].

CA) and subsequently with HRP conjugate. Finally, the
signal was shown with DAB substrate and counterstained
with hematoxylin. Three different areas of each section
were evaluated.

Real-time quantitative RT-PCR

Western blot was performed as described
previously [15, 47]. Samples containing equal amounts
of protein extracted from heart tissue lysis were loaded
into 10–15% SDS-PAGE, and then transferred to a
nitrocellulose membrane. Blocking the membrane for 1 h
at room temperature with 3% BSA. The membrane was
incubated overnight at 4°C with the primary antibody. The
signals were detected with the ECL system (Amersham
Biosciences) and quantified by scanning densitometry
using a Bio-Image Analysis System (Bio-Rad). Antiphospho-p38 MAPK, anti-p38 MAPK, anti-JNK, antiphospho-JNK, anti-ERK, anti-phospho-ERK, anti-Arrb2
and GAPDH antibodies were obtained from Cell Signaling
Technology (Beverly, MA).

Western blot analysis

The real-time PCR detection technique was
performed as described in our previous publications [30, 46].
Total RNA was isolated from mouse heart using an
RNeasy Plus Mini Kit (QIAGEN Sciences, MD). One
microgram of RNA from each sample was used for reverse
transcription using a Reaction Ready™ first strand cDNA
synthesis kit (SABiosciences, Frederick, MD). PCR was
performed using real-time™ SYBR Green Fluorescein
PCR Master Mix (SABiosciences). GAPDH expression
was used as an internal control. The primer sequences
used were as follows: TNF-α sense 5′-AGG CAC TCC
CCC AAA AGA TG-3′, antisense 5′-TCA CCC CGA AGT
TCA GTA GAC AGA-3′; IFN-γ sense 5′-AGG AAC TGG
CAA AAG GAT GGT GAC-3′, antisense 5′-TGA CGC
TTA TGT TGT TGC TGA TGG-3′; IL-10 sense 5′-TGC
TAA CCG ACT CCT TAA TGC AGG AC-3′, antisense 5′CCT TGA TTT CTG GGC CAT GCT TCT C-3′; GAPDH
sense 5′-TGA CCA CAG TCC ATG CCA TC-3′, antisense
5′-GAT GGG GGT TAC ACA GGC AG-3′.

ELISA for cytokine assay
Blood was collected from the experimental and
control mice to determine the serum level of cytokines as
described by us [46]. Samples were allowed to clot for
2 h at room temperature before centrifugation for 20 min
at 2000 g. Then serum was removed and stored at –80°C
for subsequent ELISA assay. The quantity of cytokines
(IFN-γ, TNF-α, IL-4 and IL-10) was examined using a
Quantikine Mouse ELISA kit (R&D Systems, MN).

Detection tissue invading neutrophils and
macrophages
Neutrophil accumulation in the myocardium was
stained with naphtol AS-D Chloroacetate Esterase (SigmaAldrich, St. Louis, MO) according to the manufacturer’s
protocol. Macrophages in heart tissues were examined
with the specific Ab F4/80 (1:50 dilution; Santa Cruz
Biotechnology, Santa Cruz, CA). Three slides from each
block were evaluated and observed with bright-field
microscopy. The results are expressed as the numbers of
macrophages/field (×40 magnification).

Statistical analysis
All quantitative data were presented as mean ± SD.
Statistical analysis of data between groups was performed
with two-tailed Student t test or one-way ANOVA for
experiments with more than two subgroups. Survival
curves were generated by the Kaplan-Meier method, and
the log-rank test was used to compare group survival.
p values < 0.05 were considered to be statistically
significant.

Immunohistochemistry
Heart tissues were immersion-fixed in 4%
buffered paraformaldehyde, embedded in paraffin.
ICH was performed with a Diaminobenzidine (DAB)
Histochemistry kit (Molecular Probes, Invitrogen, CA)
according to the manufacturer’s protocol and our previous
studies [14, 46]. Briefly, following antigen retrieval
with 1mM EDTA (pH 8.0), deparaffinized sections were
incubated in 1% Blocking Reagent solution for 1 h at 37°C
and then stained with anti-ICAM-1 (1:50 dilution; Santa
Cruz Biotechnology) and anti-VCAM-1 (1:50 dilution;
Santa Cruz Biotechnology) respectively, overnight at 4°C.
After washing, sections were incubated with biotinylated
anti-mouse IgG (H+L) (Vector Laboratories, Burlingame,
www.impactjournals.com/oncotarget
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